Improvements were seen in event-free and overall survival.
The combination improved invasive disease-free survival and distant relapse-free survival.
The 1-year overall survival rate was 71%.
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT.
The frequency of targetable alterations was roughly 22% in patients of African ancestry and those of European ancestry.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
There was no improvement in overall survival.
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Results of an online survey evaluating the experiences and preferences of patients with metastatic breast cancer were reported.
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.